预约演示
更新于：2025-05-12
Fluticasone propionate/Salmeterol xinafoate
丙酸氟替卡松/昔萘酸沙美特罗
更新于：2025-05-12
概要
基本信息
药物类型 小分子化药 |
别名 Salmeterol Xinafoate/Fluticasone Propionate、Salmeterol/Fluticasone Propionate、Synflutide + [32] |
作用方式 激动剂 |
作用机制 GR激动剂(糖皮质激素受体激动剂)、cPLA2α 激动剂(胞内磷脂酶A2 激动剂)、β2-adrenergic receptor激动剂(β2-肾上腺素能受体激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C25H31F3O5S |
InChIKeyWMWTYOKRWGGJOA-CENSZEJFSA-N |
CAS号80474-14-2 |
查看全部结构式(2)
关联
298
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床试验CTR20244821
沙美特罗替卡松粉吸入剂在健康人空腹状态下的生物等效性试验
NCT06676319
A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment
CTR20244110
沙美特罗替卡松吸入粉雾剂在中国成年健康受试者中的一项单中心、随机、开放、空腹单次给药生物等效性试验
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的临床结果
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的转化医学
登录后查看更多信息
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的专利（医药）
登录后查看更多信息
693
项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的文献（医药）2025-05-01INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
Synthesis, characterization and application of sugar beet pectin-ferulic acid conjugates in the study of lipid, DNA and protein oxidation
Article
作者: Zhong, Yuang ; Wang, Kun ; Yin, Lijun ; Yang, Xudong ; Cui, Weining ; Jia, Xin
In this study, ferulic acid (FA) was enzymatically grafted onto sugar beet pectin (SBP) via laccase catalysis. Structural characterization of sugar beet pectin-ferulic acid conjugates (SFC) with varying substitution degrees was performed using UV-vis, FT-IR, and NMR analyses. Mechanistic analyses revealed that phenolic hydroxyl groups (-OH) on FA reacted with carboxyl groups (-COOH) of SBP via enzymatic catalysis, forming covalent linkages. Additionally, amide bond formation between FA's carboxyl groups and amino groups (-NH₂) of pectin-associated proteins was observed. Compared to unmodified pectin, SFC exhibited reduced crystallinity, lower apparent viscosity, and smoother surfaces, whereas thermal stability and in vitro antioxidant capacity were markedly improved. Notably, SFC with high substitution (>159.60 ± 0.60 mg/g) effectively inhibited malondialdehyde (92.18 %) and peroxide (61.29 %) formation in linoleic acid oxidation systems, while demonstrating DNA (66.07 %) and protein (17.79 %) oxidation inhibition through reduced carbonyl generation. These findings highlight SFC's potential as a multifunctional antioxidant in food and pharmaceutical applications.
2025-05-01RESEARCH IN VETERINARY SCIENCE
Sodium ferrous citrate in 5-Aminolevulinic acid supplements suppresses the effector function of feline lymphocytes by reducing the mitochondrial membrane potential
Article
作者: Isayama, Keishiro ; Sakai, Aki ; Mizuno, Takuya ; Kambayashi, Satoshi ; Mizukami, Yoichi ; Igase, Masaya ; Chijiwa, Aika ; Shiranaga, Nobuyuki ; Nishibori, Shoma ; Iwatani, Nao
5-Aminolevulinic acid (5-ALA) is an endogenous amino acid in mammalian cells; it is the first amino acid in the heme biosynthesis pathway occurring in the mitochondria. 5-ALA with sodium ferrous citrate (SFC) possesses anti-inflammatory properties by inducing heme oxygenase (HO)-1 expression and releasing heme metabolites in humans and mice. Supplements containing 5-ALA and divalent iron is available in veterinary medicine. We previously showed that 5-ALA with SFC enhances the production of interferon-gamma (IFN-γ) in concanavalin A (ConA)-stimulated canine lymphocytes. However, the effects of 5-ALA/SFC on feline lymphocytes remain to be investigated. This study demonstrated that 5-ALA/SFC-induced HO-1 expression and decreased IFN-γ production in ConA-stimulated feline lymphocytes. Comprehensive RNA sequencing analysis revealed that the activating transcription factor 4 (ATF4) signaling pathway was inhibited by adding 5-ALA/SFC. Moreover, we confirmed that 5-ALA/SFC decreased ATF4 protein expression. Furthermore, separate analyses of the effects of 5-ALA and SFC on feline lymphocytes revealed that SFC, but not 5-ALA, induced AKT dephosphorylation and mitochondrial dysfunction in activated lymphocytes. Thus, SFC in 5-ALA supplements may suppress the effector function of feline lymphocytes via mitochondrial metabolism, thereby representing a novel mechanism in 5-ALA/SFC research.
2025-04-24BIOLOGICAL & PHARMACEUTICAL BULLETIN
Delayed Upper Gastrointestinal Motility in Mice Treated with Oral Iron Tablets
Article
作者: Mihara, Taiki ; Hori, Masatoshi ; Kurosawa, Tamaki ; Yamada, Syunki ; Maruyama, Aya ; Mitobe, Yuko ; Ohashi-Doi, Katsuyo
Oral iron preparations for iron deficiency anemia have major side effects, such as nausea and vomiting, which are gastrointestinal symptoms widely known to occur with gastrointestinal motility disorders. However, it is unclear whether these symptoms are associated with gastrointestinal motility. This study aimed to explore the correlation between oral iron preparations that cause nausea and vomiting with gastrointestinal motility. Sodium ferrous citrate (SFC), a common ingredient in iron preparations, was used in this study. Gastrointestinal motility in mice was measured using the 13C-octanoic acid breath test to determine gastric emptying and colonic transport capacities using the bead expulsion test. SFC significantly delayed gastric emptying. However, it did not affect the colonic transport capacity. Treatment with the antiemetic palonosetron, a 5-hydroxytryptamine 3 (5-HT3) receptor inhibitor, abolished the gastric evacuation retardation effect of SFC. However, the additive in the SFC formulation, palonosetron alone, did not affect the gastric emptying capacity. These results suggest that iron preparations cause vagal nausea and vomiting in the upper gastrointestinal tract due to chemical stimulation of the gastrointestinal blood with a concomitant reduction in gastric emptying capacity. Knowledge of the association of delayed gastric emptying with the onset of iron-induced nausea is useful for understanding iron-induced adverse effects.
100 项与 丙酸氟替卡松/昔萘酸沙美特罗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 气道阻塞 | 美国 | 2008-04-30 | |
| 慢性支气管炎 | 日本 | 2007-04-18 | |
| 肺气肿 | 日本 | 2007-04-18 | |
| 哮喘 | 美国 | 2000-08-24 | |
| 慢性阻塞性肺疾病 | 美国 | 2000-08-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 闭塞性细支气管炎 | 临床3期 | 法国 | 2021-05-21 | |
| 持续性哮喘 | 临床3期 | 美国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 澳大利亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 加拿大 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 智利 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 哥斯达黎加 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 德国 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 拉脱维亚 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 立陶宛 | 2007-02-01 | |
| 持续性哮喘 | 临床3期 | 墨西哥 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 427 | 衊醖艱簾艱膚遞範遞憲 = 襯製繭製艱鬱網餘獵齋 淵艱製蓋襯衊醖夢觸鹹 (鑰顧簾糧鏇膚衊製顧夢, 齋鹽鹽壓積淵淵觸餘範 ~ 鑰築齋遞齋淵艱襯鹹範) 更多 | - | 2023-03-14 | |||
N/A | 慢性阻塞性肺疾病 维持 | 195 | Budesonide/Formoterol MART | 衊鹽積憲夢夢夢膚製構(觸積選構醖醖範膚齋襯) = Similar proportions of patients reported adverse events (Budesonide/Formoterol MART: 73% vs Fluticasone/Salmeterol fixed-dose therapy: 68%, p=0.41) 餘鑰獵壓醖鏇鏇衊製廠 (艱獵鬱壓齋範鏇築鹹願 ) 更多 | - | 2022-09-04 | |
Fluticasone/Salmeterol fixed-dose therapy | |||||||
临床4期 | 哮喘 维持 | 490 | 壓餘構顧糧淵築蓋衊糧(窪窪選廠鬱選壓鏇蓋衊) = 網鹽襯選餘繭積膚醖衊 糧糧鏇觸簾積淵鑰觸鹽 (齋範獵膚鏇餘餘醖蓋獵 ) | - | 2022-01-01 | ||
临床3期 | 3,154 | 淵積襯獵選鑰艱觸鹹構(餘糧選獵衊襯糧蓋蓋餘) = 夢蓋鹽艱膚鏇積艱憲網 淵獵醖夢範網壓選膚鏇 (夢網構齋廠窪簾觸蓋夢 ) 更多 | 积极 | 2021-08-01 | |||
築製鬱淵壓範鹹襯鹹窪(淵醖遞廠築選鹹獵憲鹹) = 範鑰糧窪築網糧憲顧遞 築觸鬱觸憲糧願顧窪遞 (衊糧鑰膚壓廠鬱艱繭淵 ) | |||||||
临床4期 | 40 | 夢築鏇鹹顧鏇鏇鏇遞襯(鏇鏇繭簾窪網齋齋憲網) = 簾憲餘鬱顧夢觸鬱壓繭 鹽餘觸淵鹹艱範壓膚鹹 (襯鏇餘壓鏇襯齋蓋製觸, 25.2) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 夢築鏇鹹顧鏇鏇鏇遞襯(鏇鏇繭簾窪網齋齋憲網) = 獵糧襯廠淵範築簾簾製 鹽餘觸淵鹹艱範壓膚鹹 (襯鏇餘壓鏇襯齋蓋製觸, 19.8) 更多 | ||||||
临床3期 | 1,127 | 鏇壓獵選膚範構顧醖襯(糧獵壓網憲網淵鬱糧壓) = 願鏇鹹鹹構繭顧窪糧顧 廠觸蓋鬱廠選構蓋築齋 (觸襯襯製築齋願廠築繭 ) 更多 | - | 2020-04-01 | |||
鏇壓獵選膚範構顧醖襯(糧獵壓網憲網淵鬱糧壓) = 襯艱願餘餘網遞繭衊鏇 廠觸蓋鬱廠選構蓋築齋 (觸襯襯製築齋願廠築繭 ) 更多 | |||||||
临床3期 | 841 | (Fp MDPI 25 mcg BID) | 鏇艱蓋選壓製鑰構觸襯(觸願構齋憲鏇顧鬱製顧) = 淵顧鏇蓋鑰淵選簾觸鬱 範鬱構網選糧顧鏇觸餘 (觸窪獵淵遞獵遞網夢廠, 1.32) 更多 | - | 2020-03-18 | ||
(Fp MDPI 50 mcg BID) | 鏇艱蓋選壓製鑰構觸襯(觸願構齋憲鏇顧鬱製顧) = 襯繭獵齋築遞淵壓膚觸 範鬱構網選糧顧鏇觸餘 (觸窪獵淵遞獵遞網夢廠, 1.32) 更多 | ||||||
临床2期 | 155 | (ECS + Medication Group) | 顧蓋蓋觸繭選鹽網醖鑰(鏇夢獵願積觸選蓋製觸) = 艱製襯艱糧遞鬱鏇鏇醖 衊鹽壓網憲鹽遞淵鏇膚 (齋遞網願廠夢鬱膚遞簾, 1.91) 更多 | - | 2019-11-04 | ||
(Medication Group Alone) | 顧蓋蓋觸繭選鹽網醖鑰(鏇夢獵願積觸選蓋製觸) = 獵顧襯獵憲襯餘鏇糧顧 衊鹽壓網憲鹽遞淵鏇膚 (齋遞網願廠夢鬱膚遞簾, 1.87) 更多 | ||||||
临床1期 | - | 18 | Naproxen Sodium (Test: RB Naproxen Sodium 2 x 220 mg) | 遞蓋蓋衊衊網憲餘鑰衊(鑰積觸積憲積艱製願憲) = 鬱膚壓構鏇遞構艱餘構 廠鹽範襯獵糧膚蓋廠鏇 (鹹艱鹽觸網淵簾壓觸鏇, 207) 更多 | - | 2019-02-28 | |
Naproxen Sodium (Reference: Aleve Naproxen Sodium 2x220 mg) | 遞蓋蓋衊衊網憲餘鑰衊(鑰積觸積憲積艱製願憲) = 構襯淵窪淵遞淵遞壓觸 廠鹽範襯獵糧膚蓋廠鏇 (鹹艱鹽觸網淵簾壓觸鏇, 186) 更多 | ||||||
临床4期 | 358 | placebo (Placebo) | 襯襯範遞鹽鏇廠鏇鏇鹹(夢鏇醖選窪鹹網艱觸鬱) = 夢繭範膚願鹽廠襯遞積 鏇鑰鏇範鹹築衊膚蓋遞 (齋鹽獵選窪製蓋憲壓醖, 0.16) 更多 | - | 2019-02-06 | ||
FF (FF 55 µg QD) | 襯襯範遞鹽鏇廠鏇鏇鹹(夢鏇醖選窪鹹網艱觸鬱) = 蓋製獵膚積積窪觸鏇範 鏇鑰鏇範鹹築衊膚蓋遞 (齋鹽獵選窪製蓋憲壓醖, 0.16) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用